Matrix metalloproteinases in tumor invasion and metastasis

Seminars in Cancer Biology

Volumn 10, Issue 6, 2000, Pages 415-433

  Stamenkovic, Ivan ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Matrix; Metalloproteinases; Metastasis; Tumor

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; SCLEROPROTEIN;

CANCER INVASION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME STRUCTURE; EXTRAVASATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; PROTEIN DEGRADATION; REVIEW; TUMOR GROWTH;

EID: 0034472617     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2000.0379     Document Type: Article

References (171)

1. How cancer spreads
2. Principles of molecular cell biology of cancer: Cancer metastasis
3. 7th Jan Waldenstrom lecture. The biology of human cancer metastasis
4. Mechanisms of cancer metastasis: Cell biological aspects and clinical implications
5. Changing views of the role of matrix metalloproteinases in metastasis
6. Collagenolytic activity in amphibian tissues: A tissue culture assay
7. Matrix metalloproteinases: A review
8. Matrix metalloproteinase degradation of extracellular matrix: Biological consequences
9. Activation mechanisms of matrix metalloproteinases
10. Matrix metalloproteinases
11. Biochemical characterization of human collagenase-3
12. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage
13. The role of the C-terminal domain of human collagenase-3 (MMP-13) in activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction
14. Degradation of cartilage aggrecan by collagenase-3 (MMP-13)
15. Collagenase-3 (MMP-13) is expressed during human fetal ossification and reexpressed in postnatal bone remodeling and in rheumatoid arthritis
16. Matrix metalloproteinase 13 (collagenase-3) in human rheumatoid synovium
17. Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds
18. Expression of most matrix metalloproteinases family members in breast cancer represents a tumor-induced host response
19. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck
20. Human collagenase-3 is expressed in malignant squamous epithelium of the skin
21. Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor
22. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5
23. Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9
24. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells
25. Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells
26. Pharmacological inhibition of gelatinase B induction and tumor cell invasion
27. A matrix metalloproteinase expressed on the surface of invasive tumor cells
28. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP)
29. ECM and cell surface proteolysis: Regulating cellular ecology
30. The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form
31. Cellular mechanisms for human procollagenase-3 (MMP-13) activation
32. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules
33. Membrane type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases
34. Identification of soluble type of membrane-type matrix metalloproteinase-3 formed by alternatively spliced mRNA
35. Expression of three membrane-type matrix metalloproteinases (MT-MMPs) in rat vascular smooth muscle cells and characterization of MT3-MMPs with and without transmembrane domain
36. Matrix metalloproteinases: Effectors of development and normal physiology
37. Regulation of matrix metalloproteinase gene expression
38. Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors
39. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase-1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences
40. 92-kd gelatinase is actively expressed by eosinophils and stored by neutrophils in squamous cell carcinoma
41. Matrilysin expression and function in airway epithelium
42. The cystein switch: A principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family
43. Plasminogen activators and matrix metalloproteinases in angiogenesis
44. Plasminogen activators and their inhibitors: Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression
45. Role of plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells
46. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
47. Functional domains of human TIMP-1 (tissue inhibitor of metalloproteinases)
48. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin
49. Generation and activity of ternary gelatinase B/TIMP-1/LMW-stomelysin-1 complex
50. TNF-α converting enzyme (TACE) is inhibited by TIMP-3
51. Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4)
52. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues
53. Role of collagenases in tumor cell invasion
54. Tumor invasion and host extracellular matrix
55. Collagenolytic mechanisms in tumor cell invasion
56. Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade
57. Do proteases play a role in cancer invasion and metastasis?
58. Matrix metalloproteinases and tumor invasion: From correlation and causality to the clinic
59. Epidermal growth factor and oncogenes induce transcription of the same cellular mRNA in rat fibroblasts
60. The mRNA coding for the secreted protease transin is expressed more abundantly in malignant than in benign tumors
61. Human fibroblast collagenase. Complete primary structure and homology to an oncogene transformation-induced rat protein
62. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer
63. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer
64. Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas
65. Matrix metalloproteinase-2 (72 Kd type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value
66. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors
67. Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis
68. Matrix metalloproteinases and metastasis
69. Matrix metalloproteinases and the development of cancer
70. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer
71. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2)
72. TIMP-2 growth-stimulatory activity: A concentration- and cell-type specific response in the presence of insulin
73. Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells
74. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells
75. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases
76. Suppression of the tumorigenic and metastatic abilities of murin B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinase-1
77. Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibior of metalloproteinase 1 gene in nude mice
78. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor
79. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models
80. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94)
81. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice
82. Tumor targeting with a selective gelatinase inhibitor
83. Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells
84. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells
85. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system
86. Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A
87. Expression of membrane-type matrix metalloproteinase 1 (MTI-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay
88. c-fos is required for malignant progression of skin tumors
89. Tumor cell invasion inhibited by TIMP-2
90. Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor
91. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases
92. Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells
93. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay
94. The urokinase-type plasminogen activator system in cancer metastasis: A review
95. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration
96. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo
97. Stromelysin-3 expression promotes tumor take in nude mice
98. Early steps in hematogenous metastasis of B16F1 melanoma cells in chick embryos studied by highresolution intravital videomicroscopy
99. Early interactions of cancer cells with the microvasculature in mouse liver and muscle during hematogenous metastasis: Videomicroscopic analysis
100. Steps in tumor metastasis: New concepts from intravital videomicroscopy
101. In vivo videomicroscopy of experimental hematogenous metastasis: Cancer cell arrest, extravasation and migration
102. Fate of melanoma cells entering the microcirculation: Over 80% suvive and extravasate
103. Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth
104. Independence of metastatic ability and extravasation: Metastatic ras-transformed and control fibroblasts extravasate equally well
105. Up-regulation of TIMP-1 expression in B16-F10 melanoma cells suppresses their metastatic ability in chick embryo
106. Overexpression of metalloproteinase inhibitor in B16-F10 cells does not affect extravasation but reduces tumor growth
107. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: A new model for metastasis
108. Interactions between tumor cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer
109. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis
110. ECM signalling: Orchestrating cell behaviour ans misbehaviour
111. A hierarchy of ECM-mediated signaling regulates tissue-specific gene expression
112. Extracellular matrix signaling: Integration of form and function in normal and malignant cells
113. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes
114. A metalloproteinase inhibitor as an inhibitor of neovascularization
115. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase
116. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
117. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin _v _3
118. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins
119. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9)
120. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3)
121. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma
122. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis
123. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells
124. Cell-adhesion-dependent influences on genomic instability and carcinogenesis
125. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene
126. A causal role for E-cadherin in the transition from adenoma to carcinoma
127. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy
128. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin
129. The matrix metalloproteinase matrilysin influences early-stage mammary tmorigenesis
130. ADAMs: Focus on the protease domain
131. Metalloproteinase-disintegrins: Links to cell adhesion and cleavage of TNFα and notch
132. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells
133. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness
134. Proteolysis and cell migration: Creating a path?
135. The urokinase receptor is required for human monocyte chemotasis in vitro
136. Identification of the urokinase receptor as an adhesion receptor for vitronectin
137. Regulation of integrin function by the urokinase receptor
138. Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes
139. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A
140. Membrane-type matrix metalloproteinases and cell surface-associated activation cascades for matrix metalloproteinases
141. Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion
142. Proteases associated with invadopodia, and their role in degradation of extracellular matrix
143. A novel protease-docking function of integrin at invadopodia
144. RhoGAP and membrane-protrusive activities at invadopodia
145. Osteoblast-derived TGF-β1 modulates matrix degrading protease expression and activity in prostate cancer cells
146. Osteoblasts modulate secretion and activation of urokinase type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and Matrigel invasion
147. High affinity binding of latent ma trix metalloproteinase-9 to the α2(IV) chain of collagen IV
148. 3,8-10 is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells
149. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion
150. Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis
151. EMMPRIN (CD147) an inducer of matrix metalloproteinase synthesis also binds interstitial collagenase to the tumor cell surface
152. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily
153. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells
154. Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (Matrix metalloproteinase 7)
155. Regulation of cell invasion and morphogenesis in a three dimensional type collagen I matrix by membrane type matrix metalloproteinases 1, 2 and 3
156. Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three dimensional dermal collagen
157. Extrinsic regulators of epithelial tumor progression: Metalloproteinases
158. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site
159. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis
160. CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor
161. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-_ and promotes tumor invasion and angiogenesis
162. Extracellular matrix-associated transforming growth factor-β Role in cancer cell growth and invasion
163. The type 1 repeats of thrombospondin 1 activate latent trans forming growth factor-beta
164. The integrin αvβ6 binds and activates latent TGF_1: A mechanism for regulating pulmonary inflammation and fibrosis
165. Transforming growth factor-beta: Vasculogenesis, angiogenesis, and vessel wall integrity
166. Transforming growth factor type: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro
167. Metalloproteinase-mediated release of human Fas ligand
168. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase
169. Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors
170. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity
171. Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma